Forte Biosciences, Inc. (FBRX) Stock
Healthcare · Biotechnology · US
$76.50
+39.65%
Last updated Aug 3, 2026 04:32 UTC
FBRX Key Statistics
Market Cap$1.06B
P/E (TTM)-16.24
P/S (TTM)—
P/B (TTM)184.60
Revenue (TTM)$0.00
EPS (TTM)$-4.71
Dividend Yield—
ROE (TTM)-98.36%
Net Margin0.00%
Gross Margin0.00%
52W High$76.60
52W Low$15.51
Analyst ViewBuy
Price Target$65.00
Employees14
Volume17,108,344
About Forte Biosciences, Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
CEO: Paul A. Wagner. Company website
See FBRX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open FBRX in Terminal See plans